drugset
drugset / Trial / NCT05426343

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

NCT05426343 ↗

Phase 3 Completed 200 enrolled Medigen Vaccine Biologics Corp.
RandomizedParallel-groupTriple-blindPrevention

Summary

The primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titres in adult participants, in particular elderly, so as to demonstrate immunogenic superiority of MVC-COV1901 to the active control, AZD1222 vaccine, in terms of the GMT of neutralizing antibodies at 14 days after the second dose of the study intervention. This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity in terms of antigen-specific immunoglobulin as well as the potential efficacy of MVC-COV1901 in preventing COVID-19.

Timeline

Start
2022-07-09
Primary completion
2022-10-10
Completion
2023-01-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD1222 Vaccine — Intramuscular
Subject MVC-COV1901 Vaccine — Intramuscular

Indications

No indication recorded.